Ennio Antonio Chiocca

Ennio Antonio Chiocca's AcademicInfluence.com Rankings

Philosophy

#6226

World Rank

#9227

Historical Rank

Logic

#3410

World Rank

#4563

Historical Rank

philosophy Degrees

Ennio Antonio Chiocca

Biology

#8420

World Rank

#11491

Historical Rank

Molecular Biology

#1065

World Rank

#1089

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Ennio Antonio Chiocca's Degrees

Doctorate Medicine University of Padua
PhD Molecular Biology University of Padua

Why Is Ennio Antonio Chiocca Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ennio Antonio Chiocca's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

In vivo magnetic resonance imaging of transgene expression (2000) (779)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) (754)
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. (2008) (740)
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. (2008) (726)
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. (2004) (411)
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. (2010) (409)
Oncolytic Viruses in Cancer Treatment: A Review (2017) (391)
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses (1999) (347)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses (2006) (341)
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles (2018) (339)
Oncolytic Viruses and Their Application to Cancer Immunotherapy (2014) (298)
Reprogramming of the Tumor Microenvironment by Stromal Pten-regulated miR-320 (2011) (257)
Mechanisms and therapeutic implications of hypermutation in gliomas (2020) (256)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells (2015) (254)
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. (1991) (231)
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. (2005) (225)
The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors (2009) (223)
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. (1998) (219)
Multiplexed Profiling of Single Extracellular Vesicles. (2018) (207)
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. (2001) (192)
Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. (2014) (187)
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. (1994) (185)
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy (1998) (185)
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. (2006) (182)
Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. (2006) (181)
Measuring transferrin receptor gene expression by NMR imaging. (1998) (176)
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. (1997) (174)
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. (2007) (173)
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors (2012) (169)
An infectious transfer and expression system for genomic DNA loci in human and mouse cells (2001) (165)
microRNA-451: A conditional switch controlling glioma cell proliferation and migration (2010) (161)
Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant (2000) (161)
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. (1994) (160)
Treatment of glioma by engineered interleukin 4-secreting cells. (1993) (159)
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. (2001) (158)
Immunotherapy advances for glioblastoma. (2014) (158)
Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. (1994) (156)
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. (2007) (155)
Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. (1990) (152)
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases (2016) (152)
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. (1998) (149)
In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. (2002) (146)
Central nervous system cancers. (2011) (145)
The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. (2016) (140)
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients (2017) (136)
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. (1999) (135)
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial (2019) (133)
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis (2021) (132)
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. (2011) (129)
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells (2003) (129)
Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. (2008) (128)
The molecular basis of retinoic acid action. Transcriptional regulation of tissue transglutaminase gene expression in macrophages. (1988) (125)
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis (2004) (125)
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. (1994) (124)
Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. (1995) (121)
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models (2006) (121)
Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. (2011) (118)
Central nervous system cancers: Clinical Practice Guidelines in Oncology. (2005) (117)
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. (2015) (117)
Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. (2014) (116)
MRI of transgene expression: correlation to therapeutic gene expression. (2002) (114)
Emerging functions of microRNAs in glioblastoma (2009) (114)
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. (2014) (114)
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses. (2008) (112)
Quantitative analysis of complex glioma cell migration on electrospun polycaprolactone using time-lapse microscopy. (2009) (111)
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma (2000) (111)
B-myb Promoter Retargeting of Herpes Simplex Virus γ34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells (1999) (110)
Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. (2019) (109)
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. (2013) (108)
Therapeutic potential of targeting microRNA‐10b in established intracranial glioblastoma: first steps toward the clinic (2016) (108)
MicroRNAs and glioblastoma; the stem cell connection (2010) (107)
Primary Lymphoma of Peripheral Nerve: Report of Four Cases (2000) (105)
Oncolytic viruses (2002) (105)
Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. (2000) (104)
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. (2005) (103)
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. (2010) (101)
A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. (2009) (100)
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. (2013) (100)
A phase I trial of Ad.hIFN-beta gene therapy for glioma. (2008) (99)
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. (2006) (97)
Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. (2003) (97)
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. (2000) (97)
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. (1996) (91)
The complement response against an oncolytic virus is species-specific in its activation pathways. (2002) (86)
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16 (2008) (85)
Single-Step Conversion of Cells to Retrovirus Vector Producers with Herpes Simplex Virus–Epstein-Barr Virus Hybrid Amplicons (1999) (84)
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. (2008) (84)
The Histone Deacetylase Inhibitor Valproic Acid Lessens NK Cell Action against Oncolytic Virus-Infected Glioblastoma Cells by Inhibition of STAT5/T-BET Signaling and Generation of Gamma Interferon (2012) (84)
Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. (1995) (83)
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. (1998) (83)
Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. (2005) (81)
Belonging to a network--microRNAs, extracellular vesicles, and the glioblastoma microenvironment. (2015) (81)
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector (1998) (81)
A retrospective cohort-matched comparison of conscious sedation versus general anesthesia for supratentorial glioma resection. Clinical article. (2011) (79)
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. (2005) (78)
Regulation of tissue transglutaminase gene expression as a molecular model for retinoid effects on proliferation and differentiation (1989) (77)
Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. (2016) (77)
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. (1998) (76)
Strategies in Gene Therapy for Glioblastoma (2013) (75)
Gene Therapy for Brain Tumors (1995) (75)
Chondroitinase ABC I–Mediated Enhancement of Oncolytic Virus Spread and Antitumor Efficacy (2010) (74)
Glioma virus therapies between bench and bedside. (2014) (73)
Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. (1999) (72)
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma (2019) (71)
Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. (2000) (70)
Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. (1995) (70)
Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. (1995) (70)
Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours (2019) (69)
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene (2002) (68)
Interferon-stimulated Gene 15 (ISG15) and ISG15-linked Proteins Can Associate with Members of the Selective Autophagic Process, Histone Deacetylase 6 (HDAC6) and SQSTM1/p62* (2014) (68)
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy (2018) (68)
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. (2008) (67)
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma (2020) (67)
Genetic strategies for brain tumor therapy (2006) (67)
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. (2011) (66)
Oncolytic viruses driven by tumor-specific promoters. (2007) (65)
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. (1996) (64)
Directing systemic oncolytic viral delivery to tumors via carrier cells. (2010) (64)
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. (2009) (64)
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. (2012) (64)
Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. (2012) (64)
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma (2013) (62)
TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. (2015) (60)
Characterization of single microvesicles in plasma from glioblastoma patients. (2018) (59)
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. (2012) (59)
MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer (2017) (58)
Neurosurgical Delivery of Chemotherapeutics, Targeted Toxins, Genetic and Viral Therapies in Neuro-Oncology (2004) (58)
Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines (1998) (58)
Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? (2018) (58)
Replicative oncolytic herpes simplex viruses in combination cancer therapies. (2004) (56)
Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells (2004) (56)
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. (2003) (56)
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. (2013) (54)
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. (2005) (54)
Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. (1999) (54)
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. (1997) (54)
Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor. (2015) (54)
The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health. (2019) (53)
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. (2015) (53)
Oncolytic viruses as novel anticancer agents: turning one scourge against another (2000) (52)
Anti-angiogenic gene therapy in the treatment of malignant gliomas (2012) (51)
Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. (2003) (50)
Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis (2019) (50)
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation (2000) (50)
Gene and Viral Therapy for Glioblastoma: A Review of Clinical Trials and Future Directions (2012) (49)
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. (2015) (49)
Clinical and economic outcomes of low‐field intraoperative MRI‐guided tumor resection neurosurgery (2011) (48)
The status of gene therapy for brain tumors (2007) (47)
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. (2001) (47)
Design and application of oncolytic HSV vectors for glioblastoma therapy (2009) (47)
Viral therapy for glioblastoma. (2003) (47)
Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. (1961) (46)
Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5 (2002) (46)
Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. (2015) (46)
The host response to cancer virotherapy. (2008) (46)
In-training Factors Predictive of Choosing and Sustaining a Productive Academic Career Path in Neurological Surgery (2012) (45)
Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. (2009) (43)
Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. (1990) (43)
Pharmacologic and chemical adjuvants in tumor virotherapy. (2009) (42)
Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice. (2012) (42)
Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. (2001) (42)
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma (2018) (42)
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. (2015) (41)
MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma (2015) (41)
An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma (2018) (41)
The subtemporal-transpetrous approach for excision of petroclival tumors. (1996) (40)
Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. (1996) (40)
Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors (2002) (40)
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma (2018) (39)
Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. (2003) (39)
Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. (2015) (39)
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. (2008) (38)
Oncolytic viruses (2002) (38)
Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models (2017) (38)
Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. (1995) (38)
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. (2002) (37)
The Gs-Linked Receptor GPR3 Inhibits the Proliferation of Cerebellar Granule Cells during Postnatal Development (2009) (37)
Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. (2020) (36)
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma (2016) (36)
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. (2020) (36)
Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene (2020) (36)
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7 (1999) (35)
Cerebrovascular Biology and the various neural barriers: challenges and future directions. (1999) (35)
Letter: Adaptation Under Fire: Two Harvard Neurosurgical Services During the COVID-19 Pandemic (2020) (34)
Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma (2014) (34)
Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors (2016) (34)
Immunotherapy for glioblastoma: on the sidelines or in the game? (2017) (34)
Gene Therapy for Neurological Disorders and Brain Tumors (1997) (34)
Molecular responses to immune checkpoint blockade in glioblastoma (2019) (33)
Transglutaminases and their regulation: implications for polyamine metabolism. (1988) (32)
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. (1996) (32)
Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. (2011) (32)
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. (2010) (32)
Prognostic indicators. (2006) (31)
GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival (2019) (30)
A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. (1996) (30)
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials (2020) (30)
The Combination of Adenoviral HSV TK Gene Therapy and Radiation is Effective in Athymic Mouse Glioblastoma Xenografts without Increasing Toxic Side Effects (2004) (29)
C2/C3 pathologic fractures from polyostotic fibrous dysplasia of the cervical spine treated with percutaneous vertebroplasty (2007) (29)
MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. (2017) (29)
An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma (2021) (29)
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors (2006) (29)
The predictive value of low-field strength magnetic resonance imaging for intraoperative residual tumor detection. Clinical article. (2009) (29)
A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (2018) (29)
Growth of human schwannomas in the subrenal capsule of the nude mouse. (1990) (28)
Retinoids as Generalized Regulators of Cellular Growth and Differentiation (1988) (28)
Petroclival meningioma presenting with pathological laughter (1998) (28)
Copper Chelation Enhances Antitumor Efficacy and Systemic Delivery of Oncolytic HSV (2012) (27)
Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses (2020) (27)
Extracranial growth of glioblastoma multiforme (2015) (27)
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells (2011) (26)
Editorial. COVID-19 and academic neurosurgery (2020) (26)
STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells (2013) (25)
Central nervous system cancers. (2011) (25)
Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. (2003) (25)
Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy (2020) (25)
Stable transgene expression from HSV amplicon vectors in the brain: potential involvement of immunoregulatory signals. (2008) (25)
Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. (2007) (25)
Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy. (1997) (25)
The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme (2012) (24)
A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. (1998) (24)
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. (1998) (24)
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. (2018) (24)
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. (2018) (24)
A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. (2008) (24)
Pattern formation of glioma cells: Effects of adhesion (2007) (24)
The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells (2017) (23)
Intraoperative MRI (ioMRI) in the setting of awake craniotomies for supratentorial glioma resection. (2011) (23)
A retrospective analysis of reasons for reoperation following initially successful peripheral nerve stimulation. (2007) (23)
The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus (2013) (23)
Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse (1992) (22)
Methylation markers of malignant potential in meningiomas. (2013) (22)
Deep sylvian fissure meningioma without dural attachment in an adult: case report. (1994) (22)
The nuclear DICER–circular RNA complex drives the deregulation of the glioblastoma cell microRNAome (2020) (22)
Cancer immunotherapy: A vaccine from plant virus proteins. (2016) (21)
21 – Glioblastoma and malignant astrocytoma (2012) (21)
KLF4K409Q–mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment (2020) (21)
Immunotherapy for glioblastoma: going viral (2018) (21)
Gene Therapy: A Primer for Neurosurgeons (2003) (20)
Potential role of miRNAs and their inhibitors in glioma treatment (2010) (20)
Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons. (2009) (20)
Multicolumn infusion of gene therapy cells into human brain tumors: technical report. (2000) (19)
Gene therapy for tumors of the central nervous system. (1998) (19)
Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells (2018) (19)
Gene therapy for glioblastoma. (2006) (18)
DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant Gliomas (2013) (18)
GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies — reporting of surgically based therapeutic clinical trials (2007) (18)
Gene- and viral-based therapies for brain tumors (2009) (18)
Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. (2014) (18)
Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration (2019) (18)
Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. (2015) (18)
Anesthesia for brain tumor resection using intraoperative magnetic resonance imaging (iMRI) with the Polestar N-20 system: experience and challenges. (2009) (18)
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy (2013) (17)
FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles (2020) (17)
Modeling the effects of resection, radiation and chemotherapy in glioblastoma (2009) (17)
COVID-19 and academic neurosurgery (2020) (17)
Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF‐κB/STAT3 Signaling (2020) (17)
Progress and prospects: gene therapy clinical trials (part 1) (2007) (17)
Launching Effectiveness Research to Guide Practice in Neurosurgery: A National Institute Neurological Disorders and Stroke Workshop Report (2017) (17)
Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain (2012) (17)
Gene therapeutics: the future of brain tumor therapy? (2006) (17)
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy (2015) (17)
Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma (2017) (16)
The many functions of microRNAs in glioblastoma. (2010) (16)
Immune Escape Mediated by Exosomal PD‐L1 in Cancer (2020) (16)
Glioma and microglia, a double entendre (2016) (16)
An oncolytic herpes virus expressing E-cadherin resists NK cell clearance and improves viral spread and glioblastoma virotherapy (2018) (16)
Mutations in glioblastoma oncosuppressive pathways pave the way for oncomodulatory activity of cytomegalovirus (2013) (16)
Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. (1998) (15)
One size should not fit all: advancing toward personalized glioblastoma therapy. (2015) (15)
Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review (2003) (14)
Abstract 5336: Targeting glioma growth and invasiveness by microRNA-1. (2013) (14)
Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study (2003) (14)
How much is enough? The question of extent of resection in glioblastoma multiforme. (2014) (14)
In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells (2015) (13)
Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV (2012) (13)
Viruses in cancer therapy — from benchwarmers to quarterbacks (2018) (13)
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs (2013) (13)
Gene expression profiling of the anti-glioma effect of Cilengitide (2013) (13)
Estimating the cell density and invasive radius of three-dimensional glioblastoma tumor spheroids grown in vitro. (2007) (13)
Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. (2012) (12)
Marker Gene Transfer and Oncolysis of Human Y79 Retinoblastoma Cells Mediated by Herpes simplex Virus Mutants (1998) (12)
Experimental therapies: gene therapies and oncolytic viruses. (2016) (12)
Current State of Immune-Based Therapies for Glioblastoma. (2016) (12)
Targeting glioma-initiating cells via the tyrosine metabolic pathway. (2020) (12)
Modification of HSV-1 to an oncolytic virus. (2014) (12)
Neurogenetic surgery: current limitations and the promise of gene- and virus-based therapies. (1999) (11)
Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. Case report. (2009) (11)
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. (2019) (11)
Virus-Mediated Genetic Treatment of Rodent Gliomas (1994) (11)
Nerve growth factor protects against herpes simplex virus type 1 neurotoxicity in the rat striatum. (1994) (11)
Cytochrome p450-based gene therapies for cancer. (2004) (11)
Oncolytic viruses targeting tumor stem cells. (2014) (10)
Pharmacologic and Chemical Adjuvants in Tumor Virotherapy (2009) (10)
Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma. (2017) (9)
Editorial: Glioblastoma multiforme and laser interstitial thermal therapy. (2013) (9)
Switching a Replication-Defective Adenoviral Vector into a Replication-Competent, Oncolytic Adenovirus (2013) (9)
AI boosted molecular MRI for apoptosis detection in oncolytic virotherapy (2020) (9)
Gliomas and venous thromboembolism: how common? (2007) (9)
Human Cytomegalovirus is Present in Alveolar Soft Part Sarcoma (2017) (9)
Association between shunt-responsive idiopathic normal pressure hydrocephalus and alcohol. (2017) (9)
Retinoid--regulated expression of tissue transglutaminase in normal and leukemic myeloid cells. (1988) (8)
Oncolytic HSV Vectors and Anti-Tumor Immunity. (2020) (8)
Frameless Stereotactic Navigation during Insular Glioma Resection using Fusion of Three-Dimensional Rotational Angiography and Magnetic Resonance Imaging: A Technical Note. (2019) (8)
Redesigned reporter gene for improved proton exchange-based molecular MRI contrast (2020) (8)
Massive growth of a meningioma into the brachial plexus and thoracic cavity after intraspinal and supraclavicular resection. Case report and review of the literature. (2002) (8)
Brain Tumor Imaging and Surgical Management: The Neurosurgeon's Perspective (2006) (8)
An HSV amplicon-based helper system for helper-dependent adenoviral vectors. (2003) (8)
Hypoxic Roadmap of Glioblastoma—Learning about Directions and Distances in the Brain Tumor Environment (2020) (8)
Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies (2021) (8)
ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression. (2009) (7)
Adult Tethered Cord Syndrome Following Chiari Decompression. (2018) (7)
Extent of resection. (2011) (7)
Response to energy depletion: miR-451/AMPK loop (2015) (7)
Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics (2016) (7)
Solitary pituitary sarcoidosis with normal endocrine function: case report. (2008) (6)
Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells (2021) (6)
Modeling Cytomegalovirus Infection in Mouse Tumor Models (2015) (6)
Gene therapy of brain tumors: problems presented by physiological barriers (2000) (6)
Experimental and Clinical Gene Therapies for Brain Tumors (1998) (6)
Perioperative mortality. (2012) (6)
National Institute of Neurological Disorders and Stroke: current funding status, opportunities, challenges, emerging scientific advances, and recommendations for neurosurgery. (2020) (6)
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma. (2016) (6)
885 Braingate: Turning Thought into Action-First Experience with a Human Neuromotor Prosthesis. (2005) (6)
Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican (2021) (6)
Understanding glioma invasion: a necessity for effective therapy. (2013) (6)
Prognosis and treatment of melanoma metastases to the central nervous system: lots of retrospective data, very few certainties. (2011) (5)
Skull base chordomas and chondrosarcomas: a population-based analysis. (2015) (5)
Finding drugs against CD133+ glioma subpopulations. (2011) (5)
Being old is no fun: treatment of glioblastoma multiforme in the elderly. (2008) (5)
From localization to pathways: the continuing evolution of diffusion tensor imaging. (2014) (5)
Pneumatosis intestinalis after molecular targeted therapy. (2019) (5)
Personalizing oncolytic virotherapy? (2007) (5)
Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. (1999) (5)
Awake Craniotomy and Intraoperative MRI for Maximal Safe Resection in a Case of an Extensive Left Frontal and Insular Low-grade Glioma: 3-Dimensional Operative Video. (2015) (5)
Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword (2022) (4)
Bringing the endovascular neurosurgeon into the neuro-oncology treatment team. (2012) (4)
Multiple craniotomies. (2011) (4)
IT-05ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION. (2014) (4)
Editorial: meningioma and radiotherapy. (2012) (4)
A conditional switch controlling glioma cell proliferation and migration (2010) (4)
Guided genes for tumor warfare (2002) (4)
Reconstruction of Rare Skull Metastases Using Free Latissimus Dorsi Flap and the Role of Preoperative Embolization in Hypervascular Skull Tumors (2015) (4)
"Infectious" optimism for treatment of hepatocellular carcinoma. (2013) (4)
A review of gene therapy for the treatment of central nervous system tumors. (1999) (4)
Nanotechnology-based strategies for the diagnosis and treatment of intracranial neoplasms. (2013) (4)
IMPS-03INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA (2015) (3)
Measuring versus seeing. (2011) (3)
The HSV-1 iBAC amplicon vector for functional genomics studies into the genetic mechanisms of neurodegenerative disease (2004) (3)
Do meningioma patients benefit from antiepileptic drug treatment? (2013) (3)
A cross-talk network that facilitates tumor virotherapy (2015) (3)
Angiogenesis and Invasion (2010) (3)
Oncolytic viruses: extreme treatment for an extreme disease. (2006) (3)
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. (2020) (3)
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma. (2019) (3)
A viral strategy to ambush tumors (2011) (3)
Treatment for paragangliomas: passing the test of time. (2012) (3)
IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION (2020) (2)
DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES (2015) (2)
Use of 5-aminolevulinic acid for visualization of low-grade gliomas. (2011) (2)
Neurosurgery Research and Education Foundation funding conversion to National Institutes of Health funding. (2021) (2)
CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL (2020) (2)
Brain tumor gene therapy in mice with a novel "suicide" gene: the cyclophosphamide-activating CYP2B1 gene. (1995) (2)
Adult cerebellar glioblastomas: a distinct entity or parcel of the whole? (2013) (2)
The emerging field of oncolytic virus-based cancer immunotherapy. (2022) (2)
Stage IV melanoma. (2012) (2)
Meningioma surgery. (2011) (2)
Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database (2021) (2)
Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma. (2012) (2)
Abstract 1584: Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas (2010) (2)
Superficial greater petrosal neuropathy. (2014) (2)
Gene Therapy for the Nervous System-Status (1995) (2)
Chapter 14 – Cerebellar Tumors in Adults (2012) (2)
ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL (2018) (2)
Brain Tumors and Gliomas (2013) (2)
Editorial: radiosurgery and atypical meningiomas. (2012) (2)
CELL BIOLOGY AND SIGNALING (2010) (2)
CHAPTER 22 – Prodrug-Activation Gene Therapy (2006) (2)
Introduction: a focus on low-grade glioma. (2015) (2)
Neural expression of G protein-coupled receptors GPR3 modulates survival of neurons under hypoxic conditions (2010) (2)
Positron Emission Tomography-based Imaging of Transgene Expression Mediated by Replication-conditional , Oncolytic Herpes Simplex Virus Type 1 Mutant Vectors in Vivo 1 (2001) (2)
Convection-enhanced delivery. (2012) (2)
Von Hippel-Lindau disease and pregnancy. (2012) (2)
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
Cerebrovascular biology and the various neural barriers (1999) (2)
Editorial: Intraoperative magnetic resonance spectroscopy and gliomas. (2013) (2)
Neoplasm development after stereotactic radiosurgery for arteriovenous malformations. (2014) (2)
Biographies of international women leaders in neurosurgery. (2021) (2)
Editorial: dural tail sign. (2012) (2)
Low Karnofsky Performance Scale score and glioblastoma multiforme. (2011) (2)
Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM). (2014) (1)
LAB-CELL BIOLOGY AND SIGNALING (2012) (1)
ATIM-26. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULT RECURRENT GLIOBLASTOMA. (2017) (1)
434. Oncolytic Virotherapy Using the HSV Mutant rQNestin34.5 towards CD133+ Brain Tumor Stem Cells (2006) (1)
Increased Viral Replication Capacity Glioma Virotherapy : Effects of Innate Immune Suppression (2006) (1)
IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA (2020) (1)
Current State of Immune-Based Therapies for Glioblastoma. (2016) (1)
Virus Vector-Mediated Transfer of Drug-Sensitivity Genes for Experimental Brain Tumor Therapy (1995) (1)
Editorial: postoperative ischemia. (2013) (1)
Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor (2015) (1)
Image-guided maximal resection of intrinsic tumors. (2014) (1)
iBAC Technologies for Neurological Disease (2016) (1)
Acknowledgement of Reviewers 2012 (2013) (1)
Frontal dermoid cyst coexisting with suprasellar craniopharyngioma: a spectrum of ectodermally derived epithelial-lined cystic lesions? (2016) (1)
The Role of Radiation Therapy in Gross Totally Resected Meningiomas. (2015) (1)
Influence of p53 status on the efficacy of HSV-mediated cancer gene therapy (1998) (1)
Endoscopic Endonasal Resection of a Suprasellar Pituitary Adenoma Mimicking Tuberculum Sellae Meningioma in a Patient with an Intrasellar Persistent Trigeminal Artery (2018) (1)
Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. (2014) (1)
BTP-7, a novel peptide for therapeutic targeting of malignant brain tumors (2020) (1)
Treating glioblastoma multiforme with electrical fields. (2010) (1)
Gs-linked receptor GPR3 modulates proliferation and differentiation of cerebellar granule cell precursors (2009) (1)
[Herpes simplex type-1 virus-based vectors for gene therapy]. (2000) (1)
Abstract PR04: The role of long noncoding RNA HIF1A-AS2 in hypoxic environment of glioblastoma (2016) (1)
DDIS-19. NOVEL PEPTIDE HOMING TO GLIOMA-SPECIFIC ISOFORM OF BREVICAN SELECTIVELY TARGETS MALIGNANT BRAIN TUMORS (2017) (1)
LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY (2012) (1)
Monoclonal antibodies. (2010) (1)
No free lunch: secondary neoplasms after stereotactic radiation. (2015) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY (2012) (1)
Lower-Dose Stereotactic Radiosurgery for Small Brain Metastases: Local Control and Toxicity (2014) (1)
Cytomegalovirus Encephalopathy during Brain Tumor Irradiation (2020) (1)
Academic productivity in today's training climate: a fellowship's impact. (2015) (1)
Clinical Trials of Oncolytic Viruses for Gliomas (2007) (1)
Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas. (2020) (1)
LAB-CELL BIOLOGY AND SIGNALING (2012) (1)
The iBAC: an efficient high capacity genomic DNA expression system. (2002) (1)
Malignant Glioma without Affecting Antitumor Efficacy in In vivo Activity Oncolytic Adenovirus Inhibits Matrix Metalloproteinase Tissue Inhibitor of Metalloproteinase-3 Expression from an Updated (2005) (1)
PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2010) (0)
GENT-20. THE ROLE OF MIR-128 AND POLYCOMB REPRESSOR COMPLEXES IN RADIATION INDUCED PRONEURAL TO MESENCHYMAL SUBTYPE TRANSITION IN GLIOBLASTOMA STEM CELLS (2016) (0)
The Current Approach to Precocious Puberty: Consensus 2012 (2012) (0)
591 Comparison of two oHSV Vectors for the treatment of glioblastoma (2020) (0)
[Gene therapy for brain tumors: gene therapy for malignant brain tumors using prodrug-sensitivity genes (series 4)]. (1994) (0)
High capacity viral vectors for genomic DNA transgene delivery: Applications to gene therapy and functional genomics (2004) (0)
Advances in Brief Intraneoplastic Polymer-based Delivery of Cyclophosphamide for Intratumoral Bioconversion by a Replicating Oncolytic Viral Vector 1 (2001) (0)
158. Real-Time Visualization of Neuronal Differentiation and Neurite Projection Using an Indicator HSV Amplicon Vector (2006) (0)
Preoperative comorbidity scores and intangible neurosurgical wisdom. (2011) (0)
Abstract CT110: Phase II multicenter study of gene-mediated cytotoxic immunotherapy as an adjuvant to surgical resection for newly diagnosed malignant glioma: lessons learned from pseudo-progression and a nine-year survivor (2016) (0)
Clustering of brain tumor cells: a first step for understanding tumor recurrence (2012) (0)
Abstract 1383: The effect of a novel angiogenesis inhibitor (TM) on the efficacy of HSV-1 oncolytic virus (2010) (0)
Neurosurgical "pearls" and neurosurgical evidence. (2010) (0)
Integrative Copy Number and Mutational Analysis Improves Glioma Diagnostics (2014) (0)
A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (2018) (0)
Abstract B84: Preclinical analysis of combinatorial glioblastoma therapy with the prodrug-mediated gene therapy vector AdV-TK and immune checkpoint inhibition (2017) (0)
The current state of glioma data registries. (2022) (0)
INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA (2018) (0)
Who benefits from surgery for brain metastases? (2014) (0)
395 Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma (2021) (0)
The Neurosurgery Healthcare Team (2015) (0)
802. Rapid Conversion of HSV Resistant Cells to Sensitive Cells Using AdV-Mediated Overexpression of HSV Receptors (2004) (0)
Abstract 1514: Oncolytic viral therapy for glioblastoma induces robust natural killer cell activation (2010) (0)
CTIM-09. ENRICHED TCR/BCR VDJ REARRANGEMENTS CORRELATE WITH MRI AND SURVIVAL OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH CAN-3110 (2022) (0)
Meningioma-toward an improved understanding of the role of sex steroids in tumor development and progression. (2011) (0)
Genomic Evaluation of Brain Tumors and Gliomas (2010) (0)
Cancer Therapy: Preclinical CopperChelationEnhancesAntitumorEfficacyandSystemic Delivery of Oncolytic HSV (2012) (0)
TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS (2018) (0)
Abstract 5009: Translational efficacy of oncolytic HSV-1 in glioblastoma using a human autologousex vivoplatform, CANscript™ (2019) (0)
IMMU-12. THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID AUGMENTS THE SUSCEPTIBILITY OF ONCOLYTIC VIRUS-INFECTED GLIOBLASTOMA CELLS TO PD-1 BLOCKADE THERAPY (2017) (0)
Adverse Events in Multimodal Treatment Therapies for High-Grade Gliomas (2011) (0)
Abstract 4815: Cytomegalovirus enhances glioblastoma via PDGF-B/STAT3 pathway activation (2012) (0)
Editorial: urinary tract infection. (2012) (0)
Targeting Gamma34.5-mediated Herpes Virulence for Tumor Therapy (1999) (0)
Quantitative Analysis of Surgical Exposure and Angle of Surgical Freedom Obtained by Endoscope and Microscope in the Retrosigmoid and Various Posterior Petrosectomy Approaches to the Petroclival Region Using CT-Based Frameless Stereotaxy (2008) (0)
Uchida13MT-Suppl 1 (2013) (0)
IMMU-02. ONCOLYTIC HSV THERAPY ENHANCES GLIOBLASTOMA CONTROL VIA THE EXPANSION OF FUNCTIONAL TUMOR-SPECIFIC T CELLS AND MODULATION OF MYELOID CELL POPULATION (2018) (0)
Editorial: the management of low-grade glioma in adults. (2015) (0)
TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES (2020) (0)
CopperChelationEnhancesAntitumorEfficacyandSystemic Delivery of Oncolytic HSV (2012) (0)
Abstract A075: Preclinical analysis of combinatorial glioblastoma therapy with the prodrug-mediated gene therapy vector AdV-TK and immune checkpoint inhibition in GBM therapy (2016) (0)
Tannous et al. Respond. (2009) (0)
Low-grade gliomas and quality of life. (2014) (0)
ET-27REPLICATION AND SPREAD OF ONCOLYTIC HERPES VIRUS IN GLIOMA STEM CELLS CAN BE ENHANCED BY SPECIFIC INHIBITION OF HISTONE DEACETYLASE 6 (2014) (0)
EXTH-69. AN ENGINEERED microRNA CLUSTER FOR BROAD TARGETING OF EPIGENETIC COMPLEXES IN GBM (2017) (0)
The Role of Long Noncoding RNAs in Glioblastoma: What the Neurosurgeon Should Know. (2023) (0)
Imaging of gene therapy: basis and clinical trials (2009) (0)
Brain Surgery for Elders (2010) (0)
Stereotactic radiosurgery and atypical meningiomas. (2013) (0)
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM. (2019) (0)
DDIS-12. A FACILE, ROBUST AND PREDICTIVE IN VITRO BLOOD-BRAIN-BARRIER MODEL FOR HIGH-THROUGHPUT SCREENING AND DISCOVERY OF BRAIN-PENETRATING AGENTS (2016) (0)
The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. (2021) (0)
[Molecular imaging of transgene expression in brain tumors]. (2004) (0)
Abstract Submitted for the MAR07 Meeting of The American Physical Society Pattern formation of glioma cells: effects of adhesion EVGENIY (2012) (0)
432. Aurora A Kinase Inhibition Enhances Oncolytic Herpes Simplex Virotherapy in Models of Neuroblastoma (2015) (0)
Uchida13MT-Suppl 3 (2013) (0)
CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM) (2020) (0)
NT-08A NOVEL HIGH-THROUGHPUT MICROFLUIDIC DEVICE DESIGNED TO ACCELERATE THE DISCOVERY OF GLIOBLASTOMA-TARGETING LIGANDS FROM OBOC LIBRARIES (2014) (0)
Uchida13MT-Suppl 2 (2013) (0)
Modulation of tumor microenvironment enhances oncolytic virus therapy (2007) (0)
Adenoviral-mediated gene transfer into the canine brain in vivo. Commentary (2007) (0)
Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients. (2018) (0)
LAB-STEM CELLS (2012) (0)
STEM-09MicroRNA-128 IS A MASTER SWITCH BETWEEN PRONEURAL AND MESENCHYMAL SUBTYPE IN GLIOBLASTOMA STEM CELLS (2015) (0)
Abstract LB-293: Indirubins decrease glioma growth and invasionin vivo:A novel treatment paradigm combining antimigratory and antiangiogenic effects (2010) (0)
Abstract 2349: Evaluation of the combination of the prodrug-mediated gene therapy vector AdV-tk and immune checkpoint inhibitor for glioblastoma treatment in a syngeneic mouse model (2016) (0)
2. Gene Therapy for Malignant Glioma(Special Lecture,PS2-3 Future of Glioma Therapy,Plenary Session,The 29th Annual Meeting of The Japanese Congress of Neurological Surgeons) (2009) (0)
Abstract PO089: Comparison of Two oHSV Vectors for the Treatment of Glioblastoma (2021) (0)
Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. (2021) (0)
PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE (2020) (0)
Abstract 2990: Antigen presentation deficiency and mesenchymal differentiation underlie resistance to immunotherapy in the murine syngeneic CT2A tumor model (2023) (0)
IMPS-21EFFECT OF rQNestin 34.5 ONCOLYTIC HERPES VIRUS ON IMMUNE CHECKPOINT GENE EXPRESSION IN GLIOBLASTOMA CELLS AND EVALUATION OF THERAPEUTIC EFFICACY (2015) (0)
Mechanism of specific infection and destruction of diffuse liver metastases by a replication-competent herpes simplex virus (2000) (0)
Stroke and heart disease: the "also-rans" of radiation exposure. (2011) (0)
Performing quality research in an era of reforms. (2011) (0)
EXTH-38. A TRIPLET BIOLUMINESCENCE IMAGING SYSTEM REAL-TIME REVEALS VIRAL INFECTION, REPLICATION AND TUMOR VIABILITY IN VIVO (2016) (0)
Abstract 299: In vitro compound screening identifies enhancers of adenoviral oncolysis with Delta24-RGD in patient-derived glioblastoma stem cells (2015) (0)
Targeting Glioblastoma Invasion with GSK-3 inhibitors: Rapid Effects on the EMT Marker Vimentin (2014) (0)
Abstract LB-B19: BKM-120: a phosphatidyl-inositol-3 kinase inhibitor with anti-migratory properties in glioblastoma (2015) (0)
TMOD-26. CYTOMEGALOVIRUS PROMOTES GLIOBLASTOMA GROWTH VIA PDGF-D DRIVEN PERICYTE RECRUITMENT AND ANGIOGENESIS (2018) (0)
Oncolytic HSV therapy sensitizes glioma cells to integrin antagonists in vitro and in vivo. (2008) (0)
WHO classifi cation of central nervous system tumors 2016 : integration of histological features and molecular biomarkers for improved glioma diagnostics (2016) (0)
Identification of changes in tumor secretome upon OV therapy (2007) (0)
ATPS-98MONITORING ONCOLYTIC HSV-1 WITH NON-INVASIVE BIOLUMINESCENCE. (2015) (0)
Herpes Simplex Virus 1 for Cancer Therapy (2010) (0)
BI-03GLIOBLASTOMA-SPECIFIC AND GLIOBLASTOMA STEM CELL SUBTYPE-SPECIFIC SIGNATURES OF LONG, NON-CODING RNAs (2014) (0)
DDIS-26. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS (2018) (0)
Gene-Based and Viral-Based Therapies (2005) (0)
Abstract 1433: Analysis of tumor cell migration on electrospun nanofibers identifies STAT3 as a pro-migratory target in gliomas (2011) (0)
EXTH-23. PRECLINICAL ANALYSIS OF COMBINATORIAL GLIOBLASTOMA THERAPY WITH THE PRODRUG-MEDIATED GENE THERAPY VECTOR AdV-tk AND IMMUNE CHECKPOINT INHIBITION (2016) (0)
The molecular mechanism of retinoic acid action: Regulation of tissue transglutaminase gene expression (1988) (0)
AI-010. ACTIVATION OF THE PROTOTYPICAL SFK C-Src PROMOTES ANGIOGENESIS OF HUMAN GLIOBLASTOMA (2013) (0)
Oncolytic Viral Therapy for Glioma (2005) (0)
Introduction. Gene and viral therapy for glioblastoma multiforme (2021) (0)
ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma. (2018) (0)
ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS (2018) (0)
657. Combination Therapy with Cyclophosphamide and the Oncolytic Herpes Virus Mutant rRp450, Expressing a Cyclophosphamide Prodrug, Is Clinically Safe by Intratumoral, Intravenous, and Intracerebral Administration in an HSV-1 Susceptible Mouse Model (2006) (0)
CBMT-12. FATTY ACID SYNTHASE POSITIVE EVs AS NOVEL BIOMARKERS IN BRAIN CANCER. (2018) (0)
IMST-21. GLIOBLASTOMA-DERIVED EXTRACELLULAR VESICLES DYNAMICALLY CARRY PDL1 AND SPECIFICALLY INHIBIT CD4+ AND CD8+ T-CELL ACTIVATION AND PROLIFERATION (2016) (0)
Virotherapy treatment of central nervous system tumors (2022) (0)
Primary Lymphoma of Peripheral Nerve (2000) (0)
Nonreplicating Glioma Cells Support Oncolytic Herpes Replication If They Carry Specific Oncogene Deletions (2007) (0)
Gene- and Viral-Based Therapies for Gliomas (2011) (0)
Mir-128 CONTROLS THE ACTIVITY OF EPIGENETIC REGULATORS PRC1 AND PRC2 IN NEURAL STEM CELLS: IMPLICATIONS OF ITS LOSS IN GLIOMAGENESIS (2013) (0)
The biology of tumor cell invasion in the brain and its therapy (2013) (0)
Predicting outcomes: recursive partitioning analysis (RPA) prognostic algorithm for patients with metastatic sarcoma to the brain. (2014) (0)
Molecular and genetic characterization of meningiomas: future predictive assays and "personalized" treatment. (2013) (0)
IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE (2016) (0)
CBIO-12. SIX EXTRACELLULAR VESICLE RELATED GENES CAN EXPLAIN THE PRO-TUMORIGENIC BEHAVIOR OF HETEROGENEOUS HIGH GRADE GLIOMAS (2016) (0)
CBM-01CHARACTERIZATION OF microRNAome IN GLIOBLASTOMA STEM CELLS AND THEIR EXTRACELLULAR VESICLES (2015) (0)
20 – Infratentorial and Cerebellar Tumors (2018) (0)
Deep CEST MR Fingerprinting at 7T Reveals Tumor Apoptotic Response to Oncolytic Virotherapy In Vivo (2020) (0)
Irinotecan , in Combination with Cyclophosphamide Carboxylesterase Secreted Human Intestinal and CYP 2 B 1 Genes , Simplex Virus Type 1 Expressing the Prodrug-Activating Brain Tumor Oncolysis with Replication-Conditional Herpes (2005) (0)
IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS A BIOMARKER FOR IMMUNOTHERAPY (2017) (0)
TMOD-20. ESTABLISHMENT OF A BRAIN TUMOR MODEL WITH DYSFUNCTIONAL TUMOR IMMUNITY IN MICE AS A PLATFORM FOR IMMUNOTHERAPEUTIC EVALUATION (2016) (0)
804. Expression of Green Fluorescent Protein Modifies the Antitumor Effect of Oncolytic HSV-1 Vectors (2004) (0)
18. ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma (2018) (0)
CHAPTER 79 – Genomic Medicine, Brain Tumors and Gliomas (2009) (0)
ET-42DEVELOPMENT OF A NOVEL, FUNCTION-BLOCKING ANTI-FIBULIN-3 ANTIBODY AS TARGETED REAGENT FOR GLIOBLASTOMA (2014) (0)
P01.24 Rapid adaptation to metabolic stress depend on microRNA expression in Glioma (2017) (0)
Early Detection of Tumor Apoptotic Response to Oncolytic Virotherapy using Deep CEST MR Fingerprinting (2020) (0)
EVER, European Association for Vision and Eye Research (1998) (0)
Immunotherapy for glioblastoma: going viral (2018) (0)
Amendments: Publisher Correction: An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma (2019) (0)
ATPS-08DISCOVERY OF NOVEL GLIOMA-TARGETING PEPTIDES USING A HIGH-THROUGHPUT MICROFLUIDIC MAGNETIC-ACTIVATED SORTER (2015) (0)
The 1994 National Cancer Institute’s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas. (2021) (0)
Editorial: Tumor and antiepileptic drugs: clinical article. (2013) (0)
EXTH-53. IN VIVO QUANTITATIVE ANALYSIS OF ONCOLYTIC VIRUS-TUMOR KINETICS (2018) (0)
Magnetic resonance imaging of HSV-based in vivo transgene expression (2001) (0)
Analysis of microRNA expression in glioblastoma invasion (2007) (0)
Abstract B46: The long noncoding RNA INCA1 is a novel regulator of PD-L1 expression in tumors (2020) (0)
46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES (2020) (0)
Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors (2016) (0)
Cancer GeneTherapy Using aReplication- Competent Herpes Simplex Virus Type1Vector (1998) (0)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018) (0)
624. Effect of an Oncolytic HSV Mutant Expressing ICP34.5 under Control of a Nestin Promoter for Brain Tumor Therapy (2004) (0)
IMMU-05. IMMUNE STIMULATION AND IMMUNE CHECKPOINT INHIBITION PROVIDED BY A SINGLE AGENT: AN ONCOLYTIC HSV EXPRESSING A scFv ANTIBODY AGAINST PD-1 (2017) (0)
TGF b Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response (2015) (0)
A new transcriptionally driven oncovirus with Vstat 120 expression has antiangiogenic and anti-tumorigenic effects (2010) (0)
Editorial: functional neurooncology. (2012) (0)
Editorial: glioblastoma and surgery. (2013) (0)
Examination of the pathological mechanism of the microtubule associated protein tau using an HSV amplicon based neuronal gene delivery system (2003) (0)
Cytomegalovirus Infection Leads to Pleomorphic Rhabdomyosarcomas in Trp53 þ / (cid:2) Mice (2012) (0)
Involvement of GPR3 against apoptotic cell death during cerebellar development (2011) (0)
Performing Quality Research in an Era of Reforms (2011) (0)
CBIO-26. SUBPOPULATIONS OF CIRCULATING EXTRACELLULAR VESICLES OF GLIOBLASTOMA PATIENTS CAN BE DISTINGUISHED BY IMAGING FLOW CYTOMETRY (2017) (0)
Introduction to the issue (2003) (0)
Advances in Brief Comparative Analyses of Transgene Delivery and Expression in Tumors Inoculated with a Replication-conditional or-defective Viral Vector 1 (2001) (0)
A focus on low-grade glioma INTRODUCTION (2015) (0)
Replication conditional HSV-1 vector carrying CYP2B1 transgene combined with radiation cyclophosphamide and ganciclovir (2000) (0)
AI-27BKM-120: AN ANTI-INVASIVE CANDIDATE FOR THE TREATMENT OF GLIOBLASTOMA (2014) (0)
Abstract 3963: MicroRNA-124 and microRNA-1, commonly lost in glioma, coordinately target sphingosine kinase-1 in glioma cells (2011) (0)
Abstract B167: Targeting glioblastoma invasion with GSK-3 inhibitors: Rapid effects on vimentin dynamics. (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ennio Antonio Chiocca?

Ennio Antonio Chiocca is affiliated with the following schools:

Ennio Antonio Chiocca's Academic­Influence.com Rankings

Ennio Antonio Chiocca's Degrees

Why Is Ennio Antonio Chiocca Influential?

Ennio Antonio Chiocca's Published Works

Published Works

What Schools Are Affiliated With Ennio Antonio Chiocca?

Ennio Antonio Chiocca's AcademicInfluence.com Rankings